Report
EUR 12.88 For Business Accounts Only

AMYRIS INCO. sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of AMYRIS INCO. (US), active in the Specialty Chemicals industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date October 2, 2018, the closing price was USD 7.36 and its target price was estimated at USD 5.65.
Underlying
Amyris

Amyris is an industrial biotechnology company that applies its technology platform to engineer, manufacture and sell products into the Health and Wellness, Clean Beauty, and Flavor and Fragrance markets. The company's technology platform enables it to engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into ingredients. The company is focused on the production of Biofene?, its brand of renewable farnesene, a long-chain, branched hydrocarbon molecule that it manufactures through fermentation using engineered microbes. The company's farnesene derivatives are sold in various products as nutrition, health, skincare, fragrances, solvents, and fragrance ingredients.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch